{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060449","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.368755+00:00","generated_at":"2026-06-01T23:44:43.812843+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"enGene Holdings shareholders approve amended 2023 Incentive Equity Plan","bullets":["Shareholders approved amended 2023 Incentive Equity Plan with 25,623,625 votes for and 2,586,367 against at May 15 annual meeting.","Plan amendment changes evergreen provision to annual increase of 5% of outstanding common shares (or smaller as determined by committee).","Directors Paul Hastings (28,201,063 for), Wouter Joustra (28,212,507 for), and Lota Zoth (28,212,007 for) elected.","Appointment of auditor approved with 28,467,217 votes for, no against or abstentions.","Amended plan filed as Exhibit 10.1; effective upon shareholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060449","json":"https://secwatch.observer/filing/0000950170-24-060449.json","markdown":"https://secwatch.observer/filing/0000950170-24-060449.md","text":"https://secwatch.observer/filing/0000950170-24-060449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/0000950170-24-060449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/engn-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:44:43.812843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a97ff8377fa022a1a2b8e76df5fab0ff6f7bf0f","claim":"enGene Therapeutics Inc. shareholders approved Approval of Amendment of the enGene Holdings Inc. Incentive Equity Plan at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 2 – Approval of Amendment of the enGene Holdings Inc. Incentive Equity Plan For Against Abstain Broker Non-Votes 25,623,625 2,586,367 2,515 254,710","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/0000950170-24-060449-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-15"}],"fact_type":"shareholder_vote"},{"claim_id":"a754987c217ee6d294e317533d396e8b82c6e042","claim":"enGene Therapeutics Inc. shareholders approved Election of Directors at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 1 – Election of Directors Director Nominee For Withhold Broker Non-Votes Paul Hastings 28,201,063 11,444 254,710 Wouter Joustra 28,212,507 - 254,710 Lota Zoth 28,212,007 500 254,710","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/0000950170-24-060449-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-15"}],"fact_type":"shareholder_vote"},{"claim_id":"efc205c220fdea3100e7b856c165bd7806229307","claim":"enGene Therapeutics Inc. shareholders approved Appointment and Remuneration of Auditor at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 3 – Appointment and Renumeration of Auditor For Withhold Broker Non-Votes 28,467,217 - -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/0000950170-24-060449-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}